

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssstai642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 APR 09 BELSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 APR 09 ZDB will be removed from STN
NEWS 5 APR 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUBS
NEWS 6 APR 22 Records from ip.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 APR 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 APR 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 JUN 03 New e-mail delivery for search results now available
NEWS 10 JUN 10 MEDLINE Reload
NEWS 11 JUN 10 PCTFULL has been reloaded
NEWS 12 JUL 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 JUL 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 JUL 29 Enhanced polymer searching in REGISTRY
NEWS 15 JUL 30 NEIFIRST to be removed from STN
NEWS 16 AUG 08 CANCERLIT reload
NEWS 17 AUG 08 PHARMAMarketLetter (PHARMML) - new on STN
NEWS 18 AUG 08 NTIS has been reloaded and enhanced
NEWS 19 AUG 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 AUG 19 IFIPAT, IFICDB, and IFIUBS have been reloaded
NEWS 21 AUG 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 AUG 26 Sequence searching in REGISTRY enhanced
NEWS 23 SEP 03 JAPIO has been reloaded and enhanced
NEWS 24 SEP 16 Experimental properties added to the REGISTRY file
NEWS 25 SEP 16 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26 SEP 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 27 OCT 01 CASREACT Enriched with Reactions from 1907 to 1985

NEWS EXPRESS October 14 CURRENT WINDOWS VERSION IS V6.01.
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (General Information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 10:15:50 ON 16 OCT 2002

=> file medline, cancerlit, biosis, confsci, embase, caplus, uspatfull
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.42 0.42

FILE 'MEDLINE' ENTERED AT 10:16:48 ON 16 OCT 2002

FILE 'CANCERLIT' ENTERED AT 10:16:48 ON 16 OCT 2002

FILE 'BIOSIS' ENTERED AT 10:16:48 ON 16 OCT 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CONFSCI' ENTERED AT 10:16:48 ON 16 OCT 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'EMBASE' ENTERED AT 10:16:48 ON 16 OCT 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 10:16:48 ON 16 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:16:48 ON 16 OCT 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s lT (a) beta (a) receptor

L1 259 LT (A) BETA (A) RECEPTOR

=> s l1 and soluble

L2 93 L1 AND SOLUBLE

=> s l2 and antibody adj response

L3 0 L2 AND ANTIBODY ADJ RESPONSE

=> s l2 and antibody (10a) response

L4 16 L2 AND ANTIBODY (10A) RESPONSE

=> d l-16

L4 ANSWER 1 OF 16 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 2002269576 EMBASE

TI The complementation of lymphotoxin deficiency with LIGHT, a newly

discovered TNF family member, for the restoration of secondary lymphoid

structure and function.

AU Wang J.; Foster A.; Chin R.; Yu P.; Sun Y.; Wang Y.; Pfeiffer K.; Fu Y.-X.

CS Y.-X. Fu, Department of Pathology, The University of Chicago, 5841 S.

Maryland, Chicago, IL 60637, United States. yfu@midway.uchicago.edu

SO European Journal of Immunology. (2002) 32/7 (1969-1979).

Refs: 42

ISSN: 0014-2980 CODEN: EJIMAF

CY Germany

DT Journal: Article

FS 026 Immunology, Serology and Transplantation

LA 029 Clinical Biochemistry

SL English

L4 ANSWER 2 OF 16 USPATFULL

AN 2002:243111 USPATFULL

TI Novel molecules of the herpesvirus-entry-mediator-related protein family and use thereof

IN Busfield, Samantha J., Cambridge, MA, UNITED STATES

PA Millennium Pharmaceuticals, Inc. (U.S. corporation)

PI US 2002132297 AI 20020919

AI US 2001-934289 AI 20010821 (9)

RLI Continuation-in-part of Ser. No. US 1998-146950, filed on 3 Sep 1998, GRANTED, Pat. No. US 6287808

DT Utility

FS APPLICATION

LN.CNT 5162

INCL INCLM: 435/069.100

NCL INCLM: 435/325.000; 435/320.100; 530/350.000; 536/023.500; 536/024.310

NCLM: 435/069.100

NCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.500; 536/024.310 [7]

IC ICM: C07K014-705

ICS: C07H021-04; C12P021-02; C12N005-06; C12P021-06; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74; C12N005-00; C12N005-02; C07K001-00; C07K014-00; C07K017-00

L4 ANSWER 3 OF 16 USPATFULL

AN 2002:171619 USPATFULL

TI Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents

IN Browning, Jeffrey L., Brookline, MA, UNITED STATES

Meier, Werner, Burlington, MA, UNITED STATES

Benjamin, Christopher D., Beverly, MA, UNITED STATES

PI US 2002090366 AI 20020711

AI US 2001-931402 AI 20010816 (9)

RLI Division of Ser. No. US 1998-875560, filed on 5 Jun 1998, PATENTED A 371 of International Ser. No. WO 1996-US1386, filed on 26 Jan 1996, UNKNOWN Continuation-in-part of Ser. No. US 1995-378968, filed on 26 Jan 1995, PENDING

DT Utility

FS APPLICATION

LN.CNT 1764

INCL INCLM: 424/094.100

NCL INCLM: 424/178.100

NCLM: 424/094.100

NCLS: 424/178.100 [7]

IC ICM: A61K039-395

ICS: A61K039-40

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 16 USPATFULL

AN 2002:165182 USPATFULL

TI Nucleic acids, proteins, and antibodies

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

PI US 2002086811 AI 20020704

AI US 2001-764861 AI 20010117 (9)

PRAI US 2000-179065P 20000131 (60)

US 2000-180628P 20000204 (60)

US 2000-214886P 20000528 (60)

US 2000-217487P 20000711 (60)

US 2000-225758P 20000814 (60)

US 2000-220963P 20000726 (60)

US 2000-217496P 20000711 (60)

US 2000-225447P 20000814 (60)

US 2000-218290P 20000714 (60)

US 2000-225757P 20000814 (60)

US 2000-226868P 20000822 (60)

US 2000-216647P 20000707 (60)

US 2000-225267P 20000814 (60)

US 2000-216880P 20000707 (60)

US 2000-225270P 20000814 (60)

US 2000-251869P 20001208 (60)

US 2000-235834P 20000927 (60)

US 2000-234274P 20000921 (60)

US 2000-234223P 20000921 (60)

US 2000-228924P 20000830 (60)

US 2000-224518P 20000814 (60)

US 2000-236365P 20000929 (60)

US 2000-224519P 20000814 (60)

US 2000-220964P 20000726 (60)

US 2000-241809P 20001020 (60)

US 2000-249299P 20001117 (60)

US 2000-236327P 20000929 (60)

US 2000-241785P 20001020 (60)

US 2000-244617P 20001101 (60)

US 2000-225268P 20000814 (60)

US 2000-236368P 20000929 (60)

US 2000-251858P 20001208 (60)

US 2000-251868P 20001208 (60)

US 2000-229344P 20000901 (60)

US 2000-234997P 20000925 (60)

US 2000-229343P 20000901 (60)

US 2000-229345P 20000901 (60)

US 2000-229287P 20000901 (60)

US 2000-229513P 20000905 (60)

US 2000-231413P 20000908 (60)

US 2000-225059P 20000905 (60)

US 2000-236367P 20000929 (60)

US 2000-237033P 20001002 (60)

US 2000-237038P 20001002 (60)

US 2000-236370P 20000929 (60)

US 2000-236802P 20001002 (60)

US 2000-237037P 20001002 (60)

US 2000-237040P 20001002 (60)

US 2000-240960P 20001020 (60)

US 2000-239935P 20001013 (60)

DT Utility

FS APPLICATION

LN.CNT 22023

INCL INCLM: 514/001.000

ICS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 536/023.200

NCLM: 514/001.000

NCLS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 536/023.200 [7]

IC ICM: A61K031-00

ICS: C12C001-68; C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 5 OF 16 USPATFULL

AN 2002:157048 USPATFULL

TI APOPTOSIS INDUCING MOLECULE II AND METHODS OF USE

IN EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES

YU, GUO-LIANG, BERKELEY, CA, UNITED STATES

RUBEN, STEVEN M., OLNEY, MD, UNITED STATES

ZHANG, JUN, BETHESDA, MD, UNITED STATES

ULLRICH, STEPHEN ROCKVILLE, MD, UNITED STATES

ZHAI, YIFAN, GAITHERSBURG, MD, UNITED STATES

Human Genome Sciences (U.S. corporation)

PA US 2002081647 AI 20020627

PI US 2000252656 AI 19990219 (9)

RLI Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998, PENDING Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-822953, filed

on 21 Mar 1997, ABANDONED

PRAI US 1998-75409P 19980220 (60)
US 1996-13923P 19960322 (60)
US 1996-30157P 19961031 (60)

DT Utility
FS APPLICATION
LN.CNT 6195

INCL INCLM: 435/069.100
INCLS: 530/350.000; 530/399.000; 514/012.000; 536/023.500

NCL NCLM: 435/069.100
NCLS: 530/350.000; 530/399.000; 514/012.000; 536/023.500

IC [7]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ICS: C12P021-06; C07H021-04; C07K014-00; G01N033-53

L4 ANSWER 6 OF 16 USPTAFULL
AN 2002.136562 USPTAFULL

TI Soluble lymphotoxin-beta receptors as therapeutic agents for
the treatment of immunological disease

IN Browning, Jeffrey D., Brookline, MA, United States
Benjamin, Christopher D., Beverly, MA, United States
Hochman, Paula S., Newton, MA, United States
Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

PA US 6403087 B1 20020611

PI WO 9703687 19970206

AI US 1998-166 19980608 (9)
WO 1996-US12010 19960719

RLI Continuation-in-part of Ser. No. US 1995-505606, filed on 21 Jul 1995,
now patented, Pat. No. US 5925351

DT Utility
FS GRANTED
LN.CNT 1983

INCL INCLM: 424/134.100
INCLS: 424/134.100; 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300

NCL NCLM: 424/134.100
NCLS: 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300

IC [7]

ICM: A61K039-395
ICS: A61K038-16
530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2

EXP 530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 16 USPTAFULL
AN 2002.126357 USPTAFULL

TI APOPTOSIS INDUCING MOLECULE II

IN ERNER, REINHARD, GAITHERSBURG, MD, UNITED STATES
YU, GUO-LIANG, DARNESTOWN, MD, UNITED STATES
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES

PA ULLRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES
Human Genome Sciences, Inc. (U.S. corporation)

PI US 2002064869 A1 20020530

AI US 1998-27287 A1 19980220 (9)

RLI Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997,
ABANDONED

PRAI US 1996-30157P 19961031 (60)
US 1996-13923P 19960322 (60)

DT Utility
FS APPLICATION
LN.CNT 4242

INCL INCLM: 435/069.100; 435/325.000; 536/023.500

NCLM: 435/325.000; 536/023.500; 514/012.000; 435/007.200; 435/325.000
NCLS: 435/069.100; 435/325.000; 536/023.500; 514/012.000; 435/007.200; 435/325.000

IC [7]

ICM: G01N033-53
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;
C12N005-02; C12N005-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 16 USPTAFULL
AN 2002.72443 USPTAFULL

TI Method for the high level expression of active lymphotoxin-beta receptor
immunoglobulin chimeric proteins and their purification

IN Browning, Jeffrey, Brookline, MA, UNITED STATES
Miatkowski, Konrad, North Reading, MA, UNITED STATES
Meier, Werner, Burlington, MA, UNITED STATES

PI US 2002039580 A1 20020404

NCLM: 435/069.100; 435/325.000; 536/023.500; 514/012.000; 435/007.200; 435/325.000
NCLS: 435/069.100; 435/325.000; 536/023.500; 514/012.000; 435/007.200; 435/325.000

IC [7]

ICM: G01N033-53
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;
C12N005-02; C12N005-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 16 USPTAFULL
AN 2002.92268 USPTAFULL

TI Human G-protein Chemokine Receptor HDGNR10

IN Rosen, Craig A., Laytonville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES

PI US 2002048786 A1 20020425
US 2001-779879 A1 20010209 (9)
US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)

DT Utility
FS APPLICATION
LN.CNT 17969

INCL INCLM: 435/069.100
INCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000

NCL NCLM: 435/069.100
NCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000

IC [7]

ICM: G01N033-53
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;
C12N005-02; C12N005-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 8 OF 16 USPTAFULL
AN 2002.119846 USPTAFULL

TI Human G-protein Chemokine receptor (CCR5) HDGNR10

IN Rosen, Craig A., Laytonville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES

PI US 2002061834 A1 20020523
US 2001-779880 A1 20010209 (9)
US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)

DT Utility
FS APPLICATION
LN.CNT 18667

INCL INCLM: 514/001.000
INCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100

NCL NCLM: 514/001.000
NCLS: 530/350.000; 536/023.500; 435/325.000; 435/320.100; 435/069.100

IC [7]

ICM: A61K031-00
ICS: C07H021-04; C07K014-705; C12N005-06; C12P021-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 9 OF 16 USPTAFULL
AN 2002.92268 USPTAFULL

TI Human G-protein Chemokine Receptor HDGNR10

IN Rosen, Craig A., Laytonville, MD, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES

PI US 2002048786 A1 20020425
US 2001-779879 A1 20010209 (9)
US 2000-181258P 20000209 (60)
US 2000-187999P 20000309 (60)
US 2000-234336P 20000922 (60)

DT Utility
FS APPLICATION
LN.CNT 17969

INCL INCLM: 435/069.100
INCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000

NCL NCLM: 435/069.100
NCLS: 536/023.500; 424/130.100; 514/012.000; 435/007.200; 435/325.000

IC [7]

ICM: G01N033-53
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;
C12N005-02; C12N005-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 16 USPTAFULL
AN 2002.72443 USPTAFULL

TI Method for the high level expression of active lymphotoxin-beta receptor
immunoglobulin chimeric proteins and their purification

IN Browning, Jeffrey, Brookline, MA, UNITED STATES
Miatkowski, Konrad, North Reading, MA, UNITED STATES
Meier, Werner, Burlington, MA, UNITED STATES

PI US 2002039580 A1 20020404

NCLM: 435/069.100; 435/325.000; 536/023.500; 514/012.000; 435/007.200; 435/325.000
NCLS: 435/069.100; 435/325.000; 536/023.500; 514/012.000; 435/007.200; 435/325.000

IC [7]

ICM: G01N033-53
ICS: G01N033-567; A61K038-00; C07H021-04; C12P021-06; A61K039-395;
C12N005-02; C12N005-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 6 OF 16 USPTAFULL
AN 2002.136562 USPTAFULL

TI Soluble lymphotoxin-beta receptors as therapeutic agents for
the treatment of immunological disease

IN Browning, Jeffrey D., Brookline, MA, United States
Benjamin, Christopher D., Beverly, MA, United States
Hochman, Paula S., Newton, MA, United States
Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

PA US 6403087 B1 20020611

PI WO 9703687 19970206

AI US 1998-166 19980608 (9)
WO 1996-US12010 19960719

RLI Continuation-in-part of Ser. No. US 1995-505606, filed on 21 Jul 1995,
now patented, Pat. No. US 5925351

DT Utility
FS GRANTED
LN.CNT 1983

INCL INCLM: 424/134.100
INCLS: 424/134.100; 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300

NCL NCLM: 424/134.100
NCLS: 424/133.100; 514/002.000; 514/008.000; 530/387.100; 530/387.300

IC [7]

ICM: A61K039-395
ICS: A61K038-16
530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2

EXP 530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 16 USPTAFULL
AN 2002.126357 USPTAFULL

TI APOPTOSIS INDUCING MOLECULE II

IN ERNER, REINHARD, GAITHERSBURG, MD, UNITED STATES
YU, GUO-LIANG, DARNESTOWN, MD, UNITED STATES
RUBEN, STEVEN M., OLNEY, MD, UNITED STATES

PA ULLRICH, STEPHEN, ROCKVILLE, MD, UNITED STATES
Human Genome Sciences, Inc. (U.S. corporation)

PI US 2002064869 A1 20020530

AI US 1998-27287 A1 19980220 (9)

RLI Continuation-in-part of Ser. No. US 1997-822953, filed on 21 Mar 1997,
ABANDONED

PRAI US 1996-30157P 19961031 (60)
US 1996-13923P 19960322 (60)

DT Utility
FS APPLICATION
LN.CNT 4242

INCL INCLM: 435/069.100; 435/325.000; 536/023.500

AI US 2001-767370 AI 20010123 (9)
 RLI Continuation of Ser. No. WO 1999-US29873, filed on 16 Dec 1999, UNKNOWN
 PRAI US 1998-112752P 19981217 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1163
 INCL INCLM: 424/178.100
 NCL INCLS: 530/389.100; 435/069.700; 435/328.000; 530/351.000
 NCL INCLM: 424/178.100
 IC NCLS: 530/389.100; 435/069.700; 435/328.000; 530/351.000
 [7]
 ICM: A61K039-395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 16 USPATFULL
 AN 2002-67199 USPATFULL
 TI BAPF. inhibitors thereof and their use in the modulation of B-cell
 IN response
 Browning, Jeffrey, Brookline, MA, UNITED STATES
 Ambrose, Christine, Reading, MA, UNITED STATES
 Mackay, Fabienne, Vauluse, AUSTRALIA
 Tschoep, Jurg, Epalinges, SWITZERLAND
 Schneider, Pascal, Epalinges, SWITZERLAND
 AI US 2002037852 AI 20020328
 PRAI US 2001-911777 AI 20010724 (9)
 AI WO 2000-US1788 20000125
 US 1999-117169P 19990125 (60)
 US 1999-143228P 19990709 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2005
 INCL INCLM: 514/012.000
 NCL INCLS: 424/144.100; 424/153.100
 NCL INCLM: 514/012.000
 IC NCLS: 424/144.100; 424/153.100
 [7]
 ICM: A61K039-395
 ICS: A61K038-17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 16 USPATFULL
 AN 2002-3612 USPATFULL
 TI Reversal of viral-induced systemic shock and respiratory distress by
 IN blockade of the lymphotoxin beta pathway
 Browning, Jeffrey, Brookline, MA, UNITED STATES
 Puglielli, Maryann, Alexandria, VA, UNITED STATES
 Ahmed, Rafi, Atlanta, GA, UNITED STATES
 PI US 2002001585 AI 20020103
 RLI US 2001-829031 AI 20010409 (9)
 PRAI Continuation of Ser. No. WO 1999-US23477, filed on 8 Oct 1999, UNKNOWN
 DT Utility
 FS APPLICATION
 LN.CNT 1040
 INCL INCLM: 424/143.100
 NCL INCLS: 424/147.100; 435/328.000; 435/334.000
 NCL INCLM: 424/143.100
 IC NCLS: 424/147.100; 435/328.000; 435/334.000
 [7]
 ICM: A61K039-42
 ICS: A61K039-395; C12N005-06; C12N005-16
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 16 USPATFULL

AN 2001-196600 USPATFULL
 TI Lymphotoxin-.alpha./beta. complexes and anti-lymphotoxin-.beta. receptor
 IN antibodies as anti-tumor agents
 Browning, Jeffrey L., 32 Milton Rd., Brookline, MA, United States 02146
 Meier, Werner, 31 Bedford St., Burlington, MA, United States 01803
 Benjamin, Christopher D., 2 Oak Hill La., Beverly, MA, United States 01915
 PI US 6312691 B1 20011106
 AI WO 9622788 19960801 19980605 (8)
 US 1998-875560 19960126
 WO 1996-US1386 19980605 PCT 371 date
 19980605 PCT 102(e) date
 DT Utility
 FS GRANTED
 LN.CNT 2254
 INCL INCLM: 424/143.100
 INCLS: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;
 NCL NCLM: 530/388.750; 530/388.800; 530/388.850
 NCL INCLM: 424/143.100
 NCLS: 424/130.100; 424/144.100; 424/809.000; 530/388.220; 530/388.700;
 [7]
 ICM: A61K039-395
 EXF 424/130.1; 424/143.1; 424/144.1; 424/809; 530/388.22; 530/388.7;
 530/388.75; 530/388.8; 530/388.85
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 16 USPATFULL
 AN 2001-152716 USPATFULL
 TI Molecules of the herpesvirus-entry-mediator-related protein family and
 IN uses thereof
 Busfield, Samantha J., Cambridge, MA, United States
 PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
 corporation)
 PI US 6287808 B1 20010911
 AI US 1998-146950 19980903 (9)
 DT Utility
 FS GRANTED
 LN.CNT 3482
 INCL INCLM: 435/069.100
 INCLS: 536/023.500; 536/024.310; 435/320.100; 435/252.300; 435/325.000
 NCL NCLM: 435/069.100
 NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.500; 536/024.310
 [7]
 ICM: C12N015-12
 EXF ICS: C12N005-10; C12N016-63
 536/23.5; 536/24.31; 435/320.1; 435/325; 435/252.3; 435/366; 435/69.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 16 USPATFULL
 AN 2000-146513 USPATFULL
 TI Ligand for herpes simplex virus entry mediator and methods of use
 IN Ware, Carl E., Solana Beach, CA, United States
 PA La Jolla Institute for Allergy and Immunology, La Jolla, CA, United
 States (U.S. corporation)
 PI US 6140467 20001031
 AI US 1997-898234 19970730 (8)
 PRAI US 1997-51964P 19970707 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1522
 INCL INCLM: 530/350.000
 NCL NCLM: 530/350.000
 [7]

EXF 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 16 USPATFULL
AN 1999:81543 USPATFULL
TI Soluble lymphotoxin- β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

IN Browning, Jeffrey L.; Brookline, MA, United States
Hochman, Christopher D.; Beverly, MA, United States
Benjamin, Paula S.; Brookline, MA, United States
PA Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 525351
AI US 1995-505606 19990720
DT Utility 19950721 (8)
FS Granted
LN CNT 1968

INCL INCLM: 424/143.100
INCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.730; 530/388.850; 530/389.200

NCL NCLM: 424/143.100
NCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000; 530/387.100; 530/388.220; 530/388.230; 530/388.730; 530/388.850; 530/389.200; 530/395.000

IC [6]
ICM: A61K039-395
ICS: A61K038-16; C07K016-00; C07K016-28

EXF 514/218; 530/395; 530/387.1; 530/388.22; 530/388.23; 530/388.73; 530/388.85; 530/389.2; 424/143.1; 424/144.1; 424/145.1; 424/156.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his
(FILE 'HOME' ENTERED AT 10:15:50 ON 16 OCT 2002)

FILE 'MEDLINE, CANCELLIT, BIOSIS, CONFSCI, EMBASE, CAPLUS, USPATFULL' ENTERED AT 10:16:48 ON 16 OCT 2002

L1 259 S LT (A) BETA (A) RECEPTOR
L2 93 S L1 AND SOLUBLE
L3 0 S L2 AND ANTIBODY ADJ RESPONSE
L4 16 S L2 AND ANTIBODY (10A) RESPONSE

=> s l2 not py>1996
'1996' NOT A VALID FIELD CODE
L5 11 L2 NOT PY>1996

=> d 1-11

L5 ANSWER 1 OF 11 MEDLINE
AN 96065852 MEDLINE
DN 96065852 PubMed ID: 7578992
TI Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
AU Warzocha K; Bienvenu J; Coiffier B; Salles G
CS Service d'Hematologie, Centre Hospitalier Lyon-Sud, Universite Claude Bernard, Pierre-Benite, France.
SO EUROPEAN CYTOKINE NETWORK, (1995 Mar-Apr) 6 (2) 83-96. Ref: 143
Journal code: 9100879. ISSN: 1148-5493.

CY France
DT Journal; Article; (JOURNAL ARTICLE)

LA English
FS MEDLINE; Priority Journals
OS MEDLINE 96065852
EM 199511
ED Entered STN: 19960126
Last Updated on STN: 19970509

L5 ANSWER 4 OF 11 CANCELLIT
AN 9508382 CANCELLIT
DN 9508382 PubMed ID: 7995952
TI Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.
AU Browning J L; Douglas I; Ngam-ek A; Bourdon P R; Ehrenfels B N; Miatkowski K; Zafari M; Yampaglia A M; Lawton P; Meier W; +
CS Department of Immunology and Inflammation, Biogen, Cambridge, MA 02142.
SO JOURNAL OF IMMUNOLOGY, (1995 Jan 1) 154 (1) 33-46.
Journal code: 2985117R. ISSN: 0022-1767.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)

LA English
FS MEDLINE; Abridged Index Medicus Journals; Priority Journals
OS MEDLINE 9508382
EM 199501
ED Entered STN: 19950208
Last Updated on STN: 19970509

LA English
FS Priority Journals
EM 199511
ED Entered STN: 19960124
Last Updated on STN: 19970203
Entered Medline: 19951130

L5 ANSWER 2 OF 11 MEDLINE
AN 9508382 MEDLINE
DN 9508382 PubMed ID: 7995952
TI Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.
AU Browning J L; Douglas I; Ngam-ek A; Bourdon P R; Ehrenfels B N; Miatkowski K; Zafari M; Yampaglia A M; Lawton P; Meier W; +
CS Department of Immunology and Inflammation, Biogen, Cambridge, MA 02142.
SO JOURNAL OF IMMUNOLOGY, (1995 Jan 1) 154 (1) 33-46.
Journal code: 2985117R. ISSN: 0022-1767.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)

LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199501
ED Entered STN: 19950126
Last Updated on STN: 19970203
Entered Medline: 19950119

L5 ANSWER 3 OF 11 CANCELLIT
AN 96065852 CANCELLIT
DN 96065852 PubMed ID: 7578992
TI Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
AU Warzocha K; Bienvenu J; Coiffier B; Salles G
CS Service d'Hematologie, Centre Hospitalier Lyon-Sud, Universite Claude Bernard, Pierre-Benite, France.
SO EUROPEAN CYTOKINE NETWORK, (1995 Mar-Apr) 6 (2) 83-96. Ref: 143
Journal code: 9100879. ISSN: 1148-5493.

CY France
DT Journal; Article; (JOURNAL ARTICLE)

LA English
FS MEDLINE; Priority Journals
OS MEDLINE 96065852
EM 199511
ED Entered STN: 19960126
Last Updated on STN: 19970509

L5 ANSWER 4 OF 11 CANCELLIT
AN 9508382 CANCELLIT
DN 9508382 PubMed ID: 7995952
TI Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.
AU Browning J L; Douglas I; Ngam-ek A; Bourdon P R; Ehrenfels B N; Miatkowski K; Zafari M; Yampaglia A M; Lawton P; Meier W; +
CS Department of Immunology and Inflammation, Biogen, Cambridge, MA 02142.
SO JOURNAL OF IMMUNOLOGY, (1995 Jan 1) 154 (1) 33-46.
Journal code: 2985117R. ISSN: 0022-1767.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)

LA English
FS MEDLINE; Abridged Index Medicus Journals; Priority Journals
OS MEDLINE 9508382
EM 199501
ED Entered STN: 19950208
Last Updated on STN: 19970509

L5 ANSWER 5 OF 11 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1996:474465 BIOSIS
DN PREV19969204021
TI Proinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands.
AU Hochman, Paula S. (1); Majeau, Gerard R.; Mackay, Fabienne; Browning, Jeffrey L.
CS (1) Biogen, 14 Cambridge Center, Cambridge, MA 02142 USA
SO Journal of Inflammation, Vol. 46, No. 4, pp. 220-234.
DT Article
LA English

L5 ANSWER 6 OF 11 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1995:479746 BIOSIS
DN PREV199598494046
TI Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
AU Warzocha, Krzysztof; Bienvenu, Jacques; Coiffier, Bertrand; Salles, Gilles
CS (1) Serv. d'Hematol., Cent. Hosp. Lyon-Sud, 69495 Pierre-Benite Cedex France
SO European Cytokine Network, (1995) Vol. 6, No. 2, pp. 83-96.
DT General Review
LA English

L5 ANSWER 7 OF 11 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1995:73629 BIOSIS
DN PREV199598087929
TI Characterization of surface lymphotoxin forms: Use of specific monoclonal antibodies and soluble receptors.
AU Browning, Jeffrey L. (1); Douglas, Irene; Ngam-Ek, Apinya; Bourdon, Paul R.; Ehrenfels, Barbara N.; Miatkowski, Konrad; Zafari, Mohammad; Yampaglia, Alfred M.; Lawton, Pornsri; Meier, Werner; Benjamin, Christopher P.; Hession, Catherine
CS (1) Dep. Cell Biol., Biogen Inc., 14 Cambridge Center, Cambridge, MA 02142 USA
SO Journal of Immunology, (1995) Vol. 154, No. 1, pp. 33-46.
DT Article
LA English

L5 ANSWER 8 OF 11 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 95218248 EMBASE
DN 1995218248
TI Mechanism of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
AU Warzocha K.; Bienvenu J.; Coiffier B.; Salles G.
CS Service d'Hematologie, Centre Hospitalier Lyon-Sud, 69495 Pierre-Benite Cedex, France
SO European Cytokine Network, (1995) 6/2 (83-96).
DT Journal: General Review
FS 026 Immunology, Serology and Transplantation
LA English
SL English

L5 ANSWER 9 OF 11 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 95006487 EMBASE
DN 1995006487
TI Characterization of surface lymphotoxin forms: Use of specific monoclonal

antibodies and soluble receptors.
AU Browning J.L.; Douglas I.; Ngam-Ek A.; Bourdon P.R.; Ehrenfels B.N.; Miatkowski K.; Zafari M.; Yampaglia A.M.; Lawton P.; Meier W.; Benjamin C.P.; Hession C.
CS Department of Cell Biology, Biogen Inc., 14 Cambridge Center, Cambridge, MA 02142, United States
SO Journal of Immunology, (1995) 154/1 (33-46).
DT ISSN: 0022-1767 CODEN: JOIMA3
CY United States
FS 026 Immunology, Serology and Transplantation
DT 029 Clinical Biochemistry
LA English
SL English

L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1995:845171 CAPLUS
DN 123:282937
TI Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system
AU Warzocha, Krzysztof; Bienvenu, Jacques; Coiffier, Bertrand; Salles, Gilles
CS Centre Hospitalier Lyon-Sud, Universite Claude Bernard, Pierre-Benite, 69495, Fr.
SO European Cytokine Network (1995), 6(2), 83-96
DT CODEN: ECTNEJ; ISSN: 1148-5493
LA Libbey Eurotext
DT Journal: General Review
LA English

L5 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1995:280282 CAPLUS
DN 122:53732
TI Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors
AU Browning, Jeffrey L.; Douglas, Irene; Ngam-ek, Apinya; Bourdon, Paul R.; Ehrenfels, Barbara N.; Miatkowski, Konrad; Zafari, Mohammad; Yampaglia, Alfred M.; Lawton, Pornsri; et al.
CS Biogen, Cambridge, MA 02142, USA
SO Journal of Immunology (1995), 154(1), 33-46
DT CODEN: JOIMA3; ISSN: 0022-1767
LA American Association of Immunologists
DT Journal
LA English

=> d his
(FILE 'HOME' ENTERED AT 10:15:50 ON 16 OCT 2002)

FILE 'MEDLINE, CANCELIT, BIOSIS, CONFSCI, EMBASE, CAPLUS, USPATFULL' ENTERED AT 10:16:48 ON 16 OCT 2002
L1 259 S LT (A) BETA (A) RECEPTOR
L2 93 S L1 AND SOLUBLE
L3 0 S L2 AND ANTIBODY ADJ RESPONSE
L4 16 S L2 AND ANTIBODY (10A) RESPONSE
L5 11 S L2 NOT PY=>1996
=> s l2 not PY=>1997
'1997' NOT A VALID FIELD CODE
L6 34 L2 NOT PY=>1997
=> d 1-34

L6 ANSWER 1 OF 34 MEDLINE
AN 97079154 MEDLINE

DN 97079154 PubMed ID: 8920886
 TI Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs.
 AU Rennett P D; Browning J L; Mebius R; Mackay F; Hochman P S
 CS Biogen Inc., Cambridge, Massachusetts 02142, USA.
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1996 Nov 1) 184 (5) 1999-2006.
 Journal code: 2985109R. ISSN: 0022-1007.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199612
 ED Entered STN: 19970128
 Last Updated on STN: 19970128
 Entered Medline: 19961230

L6 ANSWER 2 OF 34 MEDLINE
 AN 97075125 MEDLINE
 DN 97075125 PubMed ID: 8917551
 TI Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein.
 AU Ettinger R; Browning J L; Michie S A; van Ewijk W; McDevitt H O
 CS Department of Microbiology and Immunology, Stanford University School of Medicine, CA 94305, USA.
 NC AI-36535 (NIAID)
 CA-48734 (NCI)
 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1996 Nov 12) 93 (23) 13102-7.
 Journal code: 7505876. ISSN: 0027-8424.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199612
 ED Entered STN: 19970128
 Last Updated on STN: 19970128
 Entered Medline: 19961230

L6 ANSWER 3 OF 34 MEDLINE
 AN 97033049 MEDLINE
 DN 97033049 PubMed ID: 8878796
 TI Proinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands.
 AU Hochman P S; Majewski G R; Mackay F; Browning J L
 CS Biogen, Cambridge, Massachusetts 02142, USA.
 SO JOURNAL OF INFLAMMATION, (1995-96) 46 (4) 220-34.
 Journal code: 9511967. ISSN: 1078-7852.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199701
 ED Entered STN: 19970128
 Last Updated on STN: 19970128
 Entered Medline: 19970116

L6 ANSWER 4 OF 34 MEDLINE
 AN 96228308 MEDLINE
 DN 96228308 PubMed ID: 8642291
 TI Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines.
 AU Browning J L; Miatkowski K; Sizing I; Griffiths D; Zafari M; Benjamin C D; Meier W; Mackay F
 CS Department of Immunology and Inflammation, Biogen, Cambridge,

SO Massachusetts 02142, USA.
 Journal code: 2985109R. ISSN: 0022-1007.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199607
 ED Entered STN: 19960726
 Last Updated on STN: 19970203
 Entered Medline: 19960716

L6 ANSWER 5 OF 34 MEDLINE
 AN 96065852 MEDLINE
 DN 96065852 PubMed ID: 7578992
 TI Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
 AU Warzocha K; Bienvenu J; Coiffier B; Salles G
 CS Service d'Hematologie, Centre Hospitalier Lyon-Sud, Universite Claude Bernard, Pierre-Benite, France.
 SO EUROPEAN CYTOKINE NETWORK, (1995 Mar-Apr) 6 (2) 83-96. Ref: 143
 Journal code: 9100879. ISSN: 1148-5493.
 CY France
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, ACADEMIC)
 LA English
 FS Priority Journals
 EM 199511
 ED Entered STN: 19960124
 Last Updated on STN: 19970203
 Entered Medline: 19951130

L6 ANSWER 6 OF 34 MEDLINE
 AN 95083382 MEDLINE
 DN 95083382 PubMed ID: 7995952
 TI Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.
 AU Browning J L; Douglas I; Ngam-ek A; Bourdon P R; Ehrenfels B N; Miatkowski K; Zafari M; Yampaglia A M; Lawton P; Meier W; +
 CS Department of Immunology and Inflammation, Biogen, Cambridge, MA 02142.
 SO JOURNAL OF IMMUNOLOGY, (1995 Jan 1) 154 (1) 33-46.
 Journal code: 2985117R. ISSN: 0022-1767.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199501
 ED Entered STN: 19950126
 Last Updated on STN: 19970203
 Entered Medline: 19950119

L6 ANSWER 7 OF 34 CANCELIT
 AN 97079154 CANCELIT
 DN 97079154 PubMed ID: 8920886
 TI Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs.
 AU Rennett P D; Browning J L; Mebius R; Mackay F; Hochman P S
 CS Biogen Inc., Cambridge, Massachusetts 02142, USA.
 SO JOURNAL OF EXPERIMENTAL MEDICINE, (1996 Nov 1) 184 (5) 1999-2006.
 Journal code: 2985109R. ISSN: 0022-1007.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS MEDLINE; Priority Journals

OS MEDLINE 97079154
EM 199612
ED Entered STN: 19970205
Last Updated on STN: 19970205

L6 ANSWER 8 OF 34 CANCERLIT
AN 97075125 CANCERLIT
DN 97075125 Pubmed ID: 8917551
TI Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein.

AU Ettinger R; Browning J L; Michie S A; van Ewijk W; McDevitt H O
CS Department of Microbiology and Immunology, Stanford University School of Medicine, CA 94305, USA.
NC AI-36535 (NIAID)
CA-48734 (NCI)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. (1996 Nov 12) 93 (23) 13102-7.
Journal code: 750876. ISSN: 0027-8424.

CY United States
DT Journal; Article: (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 97075125
EM 199612
ED Entered STN: 19970205
Last Updated on STN: 19970205

L6 ANSWER 9 OF 34 CANCERLIT
AN 97033049 CANCERLIT
DN 97033049 Pubmed ID: 8878796
TI Proinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands.

AU Hochman P S; Maheu G R; Mackay F; Browning J L
CS Biogen, Cambridge, Massachusetts 02142, USA.
SO JOURNAL OF INFLAMMATION. (1995-96) 46 (4) 220-34.
Journal code: 9511967. ISSN: 1078-7852.

CY United States
DT Journal; Article: (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 97033049
EM 199701
ED Entered STN: 19970205
Last Updated on STN: 19970205

L6 ANSWER 10 OF 34 CANCERLIT
AN 96228308 CANCERLIT
DN 96228308 Pubmed ID: 8642291
TI Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines.

AU Browning J L; Miatkowski K; Sizing I; Griffiths D; Zafari M; Benjamin C D; Meier W; Mackay F
CS Department of Immunology and Inflammation, Biogen, Cambridge, Massachusetts 02142, USA.
SO JOURNAL OF EXPERIMENTAL MEDICINE. (1996 Mar 1) 183 (3) 867-78.
Journal code: 29851039. ISSN: 0022-1007.

CY United States
DT Journal; Article: (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 96228308
EM 199607
ED Entered STN: 19960807
Last Updated on STN: 19970509

L6 ANSWER 11 OF 34 CANCERLIT
AN 96065852 CANCERLIT
DN 96065852 Pubmed ID: 7578992
TI Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.

AU Warzocha K; Bienvenu J; Coiffier B; Salles G
CS Service d'Hematologie, Centre Hospitalier Lyon-Sud, Universite Claude Bernard, Pierre-Benite, France.
SO EUROPEAN CYTOKINE NETWORK. (1995 Mar-Apr) 6 (2) 83-96. Ref: 143
Journal code: 9100879. ISSN: 1148-5493.

CY France
DT Journal; Article: (JOURNAL ARTICLE)
General Review: (REVIEW)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 96065852
EM 199511
ED Entered STN: 19960126
Last Updated on STN: 19970509

L6 ANSWER 12 OF 34 CANCERLIT
AN 95088382 CANCERLIT
DN 95088382 Pubmed ID: 7995952
TI Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.

AU Browning J L; Douglas I; Ngam-ek A; Bourdon P R; Ehrenfels B N; Miatkowski K; Zafari W; Yampaglia A M; Lawton P; Meier W; +
CS Department of Immunology and Inflammation, Biogen, Cambridge, MA 02142.
SO JOURNAL OF IMMUNOLOGY. (1995 Jan 1) 154 (1) 33-46.
Journal code: 29851178. ISSN: 0022-1767.

CY United States
DT Journal; Article: (JOURNAL ARTICLE)
LA English
FS MEDLINE; Abridged Index Medicus Journals; Priority Journals
OS MEDLINE 95088382
EM 199501
ED Entered STN: 19950208
Last Updated on STN: 19970509

L6 ANSWER 13 OF 34 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:20263 BIOSIS
DN PREV199799319466
TI Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs.

AU Rennert, Paul D.; Browning, Jeffrey L.; Mebius, Reina; Mackay, Fabienne; Hochman, Paula S. (1)
CS (1) Biogen, 14 Cambridge Cent., Cambridge, MA 02142 USA
SO Journal of Experimental Medicine. (1996) Vol. 184, No. 5, pp. 1999-2006.
ISSN: 0022-1007.

DT Article
LA English

L6 ANSWER 14 OF 34 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:14199 BIOSIS
DN PREV199799313402
TI Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein.

AU Ettinger, Rachel; Browning, Jeffrey L.; Michie, Sara A.; Van Ewijk, Willem; McDevitt, Hugh O. (1)
CS (1) Dep. Microbiol. Immunol., Stanford Univ. Sch. Medicine, Stanford, CA 94305 USA
SO Proceedings of the National Academy of Sciences of the United States of

America, (1996) Vol. 93, No. 23, pp. 13102-13107.
 ISSN: 0027-8424.
 Article
 English

ANSWER 15 OF 34 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:521458 BIOSIS
 DN PREV199699243814
 TI Lymphotoxin beta receptor triggering induces activation of the nuclear
 factor kappa-B transcription factor in some cell types.
 AU Mackay, Fabienne (1); Majeau, Gerard R.; Hochman, Paula S.; Browning,
 Jeffrey L.
 CS (1) Dep. Cell Biol., Biogen Inc., 12 Cambridge Cent., Cambridge, MA 02142
 USA
 SO Journal of Biological Chemistry, (1996) Vol. 271, No. 40, pp. 24934-24938.
 ISSN: 0021-9258.
 Article
 English

ANSWER 16 OF 34 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:474465 BIOSIS
 DN PREV199699204021
 TI Proinflammatory responses are efficiently induced by homotrimeric but not
 heterotrimeric lymphotoxin ligands.
 AU Hochman, Paula S. (1); Majeau, Gerard R.; Mackay, Fabienne; Browning,
 Jeffrey L.
 CS (1) Biogen, 14 Cambridge Center, Cambridge, MA 02142 USA
 SO Journal of Inflammation, Vol. 46, No. 4, pp. 220-234.
 ISSN: 1078-7852.
 Article
 English

ANSWER 17 OF 34 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:351442 BIOSIS
 DN PREV199699073798
 TI Normal development of lymph nodes is disrupted by soluble
 LT beta receptor-Ig fusion protein.
 AU Rennett, P. J.; Browning, J. L.; Hochman, P. S.
 CS Biogen, Inc., 14 Cambridge Cent., Cambridge, MA 02142 USA
 SO European Cytokine Network, (1996) Vol. 7, No. 2, pp. 167.
 Meeting Info: 6th International Tumor Necrosis Factor Congress Rhodes,
 Greece May 8-12, 1996
 ISSN: 1148-5493.
 Conference
 English

ANSWER 18 OF 34 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:229916 BIOSIS
 DN PREV199698794045
 TI Signaling through the lymphotoxin beta receptor induces the death of some
 adenocarcinoma tumor lines.
 AU Browning, Jeffrey L. (1); Miatkowski, Konrad; Sizing, Irene; Griffiths,
 David; Zafari, Mohammad; Benjamin, Christopher D.; Meier, Werner; Mackay,
 Fabienne
 CS (1) Dep. Immunology Inflammation, Biogen, 14 Cambridge Center, Cambridge,
 MA 02142 USA
 SO Journal of Experimental Medicine, (1996) Vol. 183, No. 3, pp. 867-878.
 ISSN: 0022-1007.
 Article
 English

ANSWER 19 OF 34 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:479746 BIOSIS
 DN PREV199598494046
 TI Mechanisms of action of the tumor necrosis factor and lymphotoxin

ligand-receptor system.
 AU Warzocha, Krysztof; Bienvenu, Jacques; Coiffier, Bertrand; Salles, Gilles
 (1)
 CS (1) Serv. d'Hematol., Cent. Hosp. Lyon-Sud, 69495 Pierre-Benite Cedex
 France
 SO European Cytokine Network, (1995) Vol. 6, No. 2, pp. 83-96.
 ISSN: 1148-5493.
 General Review
 English

ANSWER 20 OF 34 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:73629 BIOSIS
 DN PREV199598087929
 TI Characterization of surface lymphotoxin forms: Use of specific monoclonal
 antibodies and soluble receptors.
 AU Browning, Jeffrey L. (1); Dougas, Irene; Ngam-Ek, Apinya; Bourdon, Paul
 R.; Ehrenfels, Barbara N.; Miatkowski, Konrad; Zafari, Mohammad;
 Yampaglia, Alfred M.; Lawton, Pornsri; Meier, Werner; Benjamin,
 Christopher P.; Hession, Catherine
 CS (1) Dep. Cell Biol., Biogen Inc., 14 Cambridge Center, Cambridge, MA 02142
 USA
 SO Journal of Immunology, (1995) Vol. 154, No. 1, pp. 33-46.
 ISSN: 0022-1767.
 Article
 English

ANSWER 21 OF 34 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 96369340 EMBASE
 DN 1996369340
 TI Surface lymphotoxin .alpha./beta. complex is required for the development
 of peripheral lymphoid organs.
 AU Rennett P.D.; Browning J.L.; Mebius R.; Mackay F.; Hochman P.S.
 CS Biogen, 14 Cambridge Center, Cambridge, MA 02142, United States
 SO Journal of Experimental Medicine, (1996) 184/5 (1999-2006).
 ISSN: 0022-1007 CODEN: JEMEA
 United States
 Journal: Article
 005 General Pathology and Pathological Anatomy
 006 Internal Medicine
 025 Hematology
 English
 SL English

ANSWER 22 OF 34 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 96348247 EMBASE
 DN 1996348247
 TI Disrupted splenic architecture, but normal lymph node development in mice
 expressing a soluble lymphotoxin-beta. receptor-IgG1 fusion
 protein.
 AU Ettinger R.; Browning J.L.; Michie S.A.; Van Ewijk W.; McDevitt H.O.
 CS Department of Microbiology, Stanford Univ. School of Medicine, Stanford, CA
 94305, United States
 SO Proceedings of the National Academy of Sciences of the United States of
 America, (1996) 93/23 (13102-13107).
 ISSN: 0027-8424 CODEN: PNAS6
 United States
 Journal: Conference Article
 026 Immunology, Serology and Transplantation
 029 Clinical Biochemistry
 English
 SL English

ANSWER 23 OF 34 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
 AN 96305803 EMBASE
 DN 1996305803

TI Lymphotoxin .beta. receptor triggering induces activation of the nuclear factor .kappa.b transcription factor in some cell types.
AU Mackay F.; Majeau G.R.; Hochman P.S.; Browning J.L.
CS Dept. of Cell Biology, Biogen Inc., Cambridge Center, Cambridge, MA 02142, United States
SO Journal of Biological Chemistry, (1996) 271(40) 24934-24938.
CY ISSN: 0021-9258 CODEN: JBCHA3
DT Journal; Article
FS United States
LA English
SL English

L6 ANSWER 24 OF 34 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 96266842 EMBASE
DN 1996266842
TI Proinflammatory responses are efficiently induced by homotrimeric but not heterotrimeric lymphotoxin ligands.
AU Hochman P.S.; Majeau G.R.; Mackay F.; Browning J.L.
CS Biogen, 14 Cambridge Center, Cambridge, MA 02142, United States
SO Journal of Inflammation, (1995) 46/4 (220-234).
CY ISSN: 1078-7852 CODEN: JOINFB
DT Journal; Article
FS United States
LA English
SL English

L6 ANSWER 25 OF 34 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 96119623 EMBASE
DN 1996119623
TI Signaling through the lymphotoxin .beta. receptors induces the death of some adenocarcinoma tumor lines.
AU Browning J.L.; Matkowski K.; Sizing I.; Griffiths D.; Zafari M.; Benjamin C.D.; Meier W.; Mackay F.
CS Dept. of Immunology and Inflammation, Biogen, 14 Cambridge Center, Cambridge, MA 02142, United States
SO Journal of Experimental Medicine, (1996) 183/3 (867-878).
CY ISSN: 0022-1007 CODEN: JEMEA
DT Journal; Article
FS United States
LA English
SL English

L6 ANSWER 26 OF 34 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 95218248 EMBASE
DN 1995218248
TI Mechanism of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
AU Warzocha K.; Bienvenu J.; Coiffier B.; Salles G.
CS Service d'Hematologie, Centre Hospitalier Lyon-Sud, 69495 Pierre-Benite Cedex, France
SO European Cytokine Network, (1995) 6/2 (83-96).
CY ISSN: 1148-5493 CODEN: ECTWNEJ
DT Journal; General Review
FS Immunology, Serology and Transplantation
LA English
SL English

L6 ANSWER 27 OF 34 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 95006487 EMBASE
DN 1995006487
TI Characterization of surface lymphotoxin forms: Use of specific monoclonal antibodies and soluble receptors.
AU Browning J.L.; Douglas I.; Ngam-Ek A.; Bourdon P.R.; Ehrenfels B.N.; Matkowski K.; Zafari M.; Yampaglia A.M.; Lawton P.; Meier W.; Benjamin C.P.; Hession C.
CS Department of Cell Biology, Biogen Inc., 14 Cambridge Center, Cambridge, MA 02142, United States
SO Journal of Immunology, (1995) 154/1 (33-46).
CY ISSN: 0022-1767 CODEN: JOIMA3
DT Journal; Article
FS Immunology, Serology and Transplantation
LA English
SL English

L6 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2002 ACS
AN 1996:692141 CAPLUS
DN 126:6161
TI Surface lymphotoxin .alpha./beta. complex is required for the development of peripheral lymphoid organs
AU Rennert, Paul D.; Browning, Jeffrey L.; Mebius, Reina; Mackay, Fabienne; Hochman, Paula S.
CS Biogen Inc., Cambridge, MA, 02142, USA
SO Journal of Experimental Medicine (1996), 184(5), 1999-2006
CODEN: JEMEA; ISSN: 0022-1007
PB Rockefeller University Press
DT Journal
LA English

L6 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2002 ACS
AN 1996:689834 CAPLUS
DN 125:325988
TI Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-.beta. receptor-IgG1 fusion protein
AU Ettinger, Rachel; Browning, Jeffrey L.; Michie, Sara A.; van Ewijk, Willem; McDevitt, Hugh O.; McDevitt, Hugh O.
CS Dep. Microbiol., Stanford Univ. School Medicine, Stanford, CA, 94305, USA
SO Proceedings of the National Academy of Sciences of the United States of America (1996), 93(23), 13102-13107
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English

L6 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2002 ACS
AN 1996:613390 CAPLUS
DN 125:271950
TI Lymphotoxin .beta. receptor triggering induces activation of the nuclear factor .kappa.B transcription factor in some cell types
AU Mackay, Fabienne; Majeau, Gerard R.; Hochman, Paula S.; Browning, Jeffrey L.
CS Dep. Cell Biol., Biogen Inc., Cambridge, MA, 02142, USA
SO Journal of Biological Chemistry (1996), 271(40), 24934-24938
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English

L6 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2002 ACS
AN 1996:586668 CAPLUS

DN 125:245232
 TI Proinflammatory responses are efficiently induced by homotrimeric but not
 AU heterotrimeric lymphotoxin ligands
 AU Hochman, Paula S.; Najean, Gerard R.; Mackay, Fabienne; Browning, Jeffrey
 L.
 CS Biogen, Cambridge, MA, 02142, USA
 DN Journal of Inflammation (1996), Volume Date 1995-1996, 46(4), 220-234
 SO CODEN: JOINF; ISSN: 1078-7852
 PB Wiley-Liss
 DT Journal
 LA English
 L6 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2002 ACS
 AN 1996:189896 CAPLUS
 DN 124:229647
 TI Signaling through the lymphotoxin .beta. receptor induces the death of
 AU some adenocarcinoma tumor lines
 AU Browning, Jeffrey L.; Miatkowski, Konrad; Sizing, Irene; Griffiths, David;
 Zafari, Mohammad; Benjamin, Christopher D.; Meier, Werner; Mackay,
 Fabienne
 CS Dep. Immunol. Inflammation Protein Eng., Biogen, Cambridge, MA, 02142, USA
 DN Journal of Experimental Medicine (1996), 183(3), 867-78
 SO CODEN: JEMED; ISSN: 0022-1007
 PB Rockefeller University Press
 DT Journal
 LA English
 L6 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2002 ACS
 AN 1995:845171 CAPLUS
 DN 123:282937
 TI Mechanisms of action of the tumor necrosis factor and lymphotoxin
 AU ligand-receptor system
 AU Warzocha, Krzysztof; Bienvenu, Jacques; Coiffier, Bertrand; Salles, Gilles
 Centre Hospitalier Lyon-Sud, Universite Claude Bernard, Pierre-Benite,
 69495, Fr.
 CS European Cytokine Network (1995), 6(2), 83-96
 DN CODEN: ECVNEJ; ISSN: 1148-5493
 PB Libbey Eurotext
 DT Journal; General Review
 LA English
 L6 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2002 ACS
 AN 1995:280282 CAPLUS
 DN 122:53732
 TI Characterization of surface lymphotoxin forms. Use of specific monoclonal
 AU antibodies and soluble receptors
 AU Browning, Jeffrey L.; Douglas, Irene; Ngam-ek, Apinya; Bourdon, Paul R.;
 Shirefells, Barbara N.; Miatkowski, Konrad; Zafari, Mohammad; Yampaglia,
 Alfred M.; Lawton, Pornari; et al.
 CS Biogen, Cambridge, MA, 02142, USA
 DN Journal of Immunology (1995), 154(1), 33-46
 SO CODEN: JOIMA3; ISSN: 0022-1767
 PB American Association of Immunologists
 DT Journal
 LA English
 => d 17 all
 L6 ANSWER 17 OF 34 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:351442 BIOSIS
 DN PREVIOUSLY 3798
 TI Normal development of lymph nodes is disrupted by soluble
 Lf beta receptor-Ig fusion protein.
 AU Rennert, P. J.; Browning, J. L.; Hochman, P. S.
 CS Biogen, Inc., 14 Cambridge Cent., Cambridge, MA, 02142 USA
 DN European Cytokine Network, (1996) Vol. 7, No. 2, pp. 167.
 SO Meeting Info.: 6th International Tumor Necrosis Factor Congress Rhodes,
 Greece May 8-12, 1996
 ISSN: 1148-5493.
 DT Conference
 LA English
 CC General Biology - Symposia, Transactions and Proceedings of Conferences,
 Congresses, Review Annals, 00520
 Biochemical Studies - Carbohydrates 10068
 Biochemical Studies - Phenomena *10508
 Biophysics - Membrane Physiology and Biochemistry *14504
 Cardiovascular System Physiology and Body Fluids - Lymphatic Tissue and
 Blood, Blood-Forming Organs *15008
 Reticuloendothelial System *17002
 Endocrine System - General *25502
 Developmental Biology - Embryology - General and Descriptive *25508
 Developmental Biology - Morphogenesis, General *34502
 Immunology and Immunochimistry - General; Methods *34502
 Muridae *86375
 BC Major Concepts
 IT Blood and Lymphatics (Transport and Circulation); Cardiovascular System
 (Transport and Circulation); Development; Endocrine System (Chemical
 Coordination and Homeostasis); Immune System (Chemical Coordination and
 Homeostasis); Membranes (Cell Biology)
 IT Miscellaneous Descriptors
 EMBRYONIC CIRCULATION; IMMUNOGLOBULIN G; LYMPHOTOXIN-BETA; MEETING
 ABSTRACT; MOUSE YOLK SAC; TUMOR NECROSIS FACTOR
 ORGN Super Taxa
 Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 Muridae (Muridae)
 ORGN Organism Superterms
 animals: chordates; mammals; nonhuman vertebrates; nonhuman mammals;
 rodents: vertebrates
 => d his
 (FILE 'HOME' ENTERED AT 10:15:50 ON 16 OCT 2002)
 FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, EMBASE, CAPLUS, USPATFULL'
 ENTERED AT 10:16:48 ON 16 OCT 2002
 259 S LT (A) BETA (A) RECEPTOR
 L1 93 S L1 AND SOLUBLE
 L2 0 S L2 AND ANTIBODY ADJ RESPONSE
 L3 16 S L2 AND ANTIBODY (10A) RESPONSE
 L4 11 S L2 NOT PY>1996
 L5 34 S L2 NOT PY>1997
 L6
 => s soluble(a)receptor? and not effective
 MISSING TERM 'AND NOT'
 The search profile that was entered contains a logical
 operator followed immediately by another operator.
 => s soluble (a)receptor? and ineffective
 L7
 =>
 ---Logging off of STN---
 =>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
125.04	125.46

STN INTERNATIONAL LOGOFF AT 10:45:05 ON 16 OCT 2002